The impact of methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism on transplant-related variables after allogeneic hematopoietic cell transplantation in patients receiving MTX as GVHD prophylaxis.
Soydan
E
E
Topcuoglu
P
P
Dalva
K
K
Arat
M
M
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D005260:Female; D006085:Graft Survival / Q000235:genetics*; D006086:Graft vs Host Disease / Q000201:enzymology / Q000235:genetics* / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007938:Leukemia / Q000201:enzymology / Q000235:genetics / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D045102:Methylenetetrahydrofolate Dehydrogenase (NAD+) / Q000235:genetics*; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D013997:Time Factors; D014184:Transplantation, Homologous; D055815:Young Adult
D007166:Immunosuppressive Agents; D045102:Methylenetetrahydrofolate Dehydrogenase (NAD+); D008727:Methotrexate